[{"orgOrder":0,"company":"Lygenesis","sponsor":"Juvenescence","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"LYG-LIV0001","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.01,"dosageForm":"","sponsorNew":"Lygenesis \/ Juvenescence","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis \/ Juvenescence"},{"orgOrder":0,"company":"Lygenesis","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"LYG-LIV0001","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ AgeX Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lygenesis \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Lygenesis","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Termination","leadProduct":"AGEX-VASC1","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ LyGenesis","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis \/ LyGenesis"},{"orgOrder":0,"company":"Lygenesis","sponsor":"Imagine Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Lygenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lygenesis \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Lygenesis \/ Imagine Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Lygenesis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The research collaboration will leverage Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 12, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Imagine Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

                          Brand Name : AGEX-VASC1

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 23, 2021

                          Lead Product(s) : AGEX-VASC1

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Recipient : AgeX Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : LYG-LIV0001 is a regenerative mobile remedy comprising allogeneic hepatocytes suspended in a buffered cell preservation resolution which are transplanted into periduodenal lymph nodes.

                          Brand Name : LYG-LIV0001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 02, 2021

                          Lead Product(s) : LYG-LIV0001

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : AgeX Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds will be used to fund LyGenesis’s Phase 2a clinical trial with a first patient in targeted for early 2021, also to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs.

                          Brand Name : LYG-LIV0001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 30, 2020

                          Lead Product(s) : LYG-LIV0001

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Juvenescence

                          Deal Size : $11.0 million

                          Deal Type : Financing

                          blank